EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics

EQT Life Science

 

Electra Therapeutics EQT

  • Electra Therapeutics is a late-stage biotechnology company developing new medicines for people with serious immunological and cancer-related diseases
  • Financing was co-led by EQT Life Sciences and Nextech, with participation from Sanofi, HBM Healthcare Investments, Mubadala Capital, and all existing investors
  • Proceeds will fund the registrational Phase 2/3 clinical study of the lead program in secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening hyperinflammatory disease with no approved therapies
  • Funding will also support expanding the lead program into hematologic cancers and establishing clinical proof-of-mechanism for a second program, with broad potential across immunology and inflammation

​​Amsterdam, The Netherlands, 22 October 2025. EQT Life Sciences is pleased to announce that its LSP 7 fund has invested in Electra Therapeutics, a late-stage US biotechnology company developing innovative treatments for immune-mediated diseases and cancer. Electra is advancing a new class of precision medicines designed to selectively target overactive immune cells that drive disease, while preserving normal immune function. This differentiated approach has the potential to deliver more effective and durable therapies for patients affected by serious immune-mediated and inflammatory conditions.

The USD 183 million Series C will fund the global registrational Phase 2/3 clinical study of the lead program (ELA026) in secondary hemophagocytic lymphohistiocytosis (sHLH) and establish clinical proof-of-mechanism for Electra’s second program (ELA822) that has broad potential across immunology. The round was co-led by EQT Life Sciences and Nextech, with participation from new investors Sanofi, HBM Healthcare Investments, and Mubadala Capital, alongside all existing investors.

sHLH is a severe and life-threatening inflammatory condition triggered by underlying diseases such as cancer, autoimmune disorders, or serious infections. It causes the immune system to go into overdrive, leading to widespread inflammation and organ failure. There are currently no FDA-approved treatments for sHLH broadly, and in cancer-associated sHLH, survival at 8 weeks is only about 50 percent with existing options. Electra’s ELA026 is an antibody targeting Signal Regulatory Proteins (SIRP), cell surface receptors found on immune cells that become overexpressed in inflammatory diseases. By precisely removing these harmful cells while sparing normal immune function, ELA026 is designed to stop the inflammatory process at its source. This approach represents a novel way to rebalance the immune system and could have broader applications across multiple immune-mediated diseases.

Early clinical data are highly encouraging. In a Phase 1b study in sHLH, ELA026 achieved 100 percent survival at 8 weeks in frontline-treated patients. While preliminary, these results support the premise that precisely depleting SIRP-expressing immune cells can rapidly restore immune balance and may represent a meaningful advance for patients with this devastating condition. ELA026 has received FDA Breakthrough Therapy and EMA Priority Medicines designations for sHLH.

“We are pleased to have the support of a distinguished group of investors who share our vision to deliver life-changing treatments for patients with underserved diseases,” said Kathy Dong, PharmD, MBA, President and CEO of Electra Therapeutics. “Our team has a proven record of translating novel biology into first-in-class breakthrough therapies, as exemplified by ELA026. With strong momentum, we are driving the pivotal study of ELA026 in sHLH forward and accelerating our second SIRP-targeted program into the clinic.”

“The Electra team has demonstrated exceptional scientific and clinical execution in advancing a first-in-class therapy for patients with no approved treatment options,” said Christoph Broja, Partner in EQT Life Sciences, who will join Electra’s board as observer. “We are impressed by the clarity of Electra’s approach and the quality of its early data, and we look forward to supporting the team as it drives its pivotal program forward and explores the broader potential of SIRP-targeted therapies to bring real innovation to patients.”

Contact

EQT Press Office, press@eqtpartners.com

Downloads

About EQT Life Sciences

EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences aims to back the smartest inventors who have ideas that could truly make a difference for patients.

More information: https://eqtgroup.com/private-capital/eqt-life-sciences

About Electra Therapeutics

Electra Therapeutics is a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer. The company’s lead product candidate, ELA026, is a first in class monoclonal antibody that targets signal regulatory proteins (SIRP) on immune cells to selectively deplete pathological myeloid cells and T lymphocytes. ELA026 is currently in pivotal development for secondary hemophagocytic lymphohistiocytosis (sHLH) and is also being evaluated in additional indications. Electra is further advancing a second SIRP-targeted program, ELA822, designed to selectively deplete activated T lymphocytes, with broad potential across immunology and inflammation (I&I). For more information, please visit www.electra-therapeutics.com and follow us on LinkedIn

Categories: News

Tags:

EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion

No Comments
EQT Life Science

EQT-ImCheck

  • Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agreement. ImCheck’s shareholders will be eligible to receive a payment of EUR 350 million and downstream payments,  for a total potential consideration of up to EUR 1 billion.
  • ImCheck Therapeutics is a private French biotechnology company pioneering next-generation immuno-oncology therapies.
  • EQT Life Sciences has backed ImCheck since 2017 and has provided comprehensive support beyond capital, at the board level.

EQT Life Sciences is pleased to announce that Ipsen (Euronext: IPN; ADR: IPSEY) has entered into a definitive agreement to acquire its portfolio company ImCheck Therapeutics for EUR 350 million at closing, with a total transaction value of up to USD 1 billion.

ImCheck Therapeutics, based in Marseille, France, is pioneering immuno-oncology therapies by targeting butyrophilins, a novel group of immune-regulating proteins. Its lead drug, ICT01, is being tested in acute myeloid leukemia (AML) patients who are not fit for standard treatment, with early Phase I/II trial results showing promising responses. ICT01 is a first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer.

EQT Life Sciences invested in the business in 2017, as part of a syndicate of investors, and has since provided comprehensive support, including at the board level.

Vincent Brichard, Venture Partner at EQT Life Sciences, said: “We are immensely proud to have supported ImCheck’s journey to this significant acquisition by Ipsen. The transaction highlights the strength of ImCheck’s platform and exceptional leadership and team. It is also a testament to our ability to identify hidden gems and support transformative biotech companies.”

Pierre d’Epenoux, CEO of ImCheck Therapeutics, said: “This transaction is an extraordinary milestone for ImCheck and puts the spotlight on groundbreaking science originating from French academia. EQT Life Sciences’ support has extended far beyond financing – their strategic guidance and confidence in my leadership has been instrumental in our success. Together, we have advanced pioneering science from concept to late-stage clinical development, demonstrating what visionary investors and dedicated teams can accomplish together.”

Together with the Amolyt Pharma exit to AstraZeneca in 2024, EQT Life Sciences has achieved successful exits from its two portfolio companies under the France 2030 investment program – a government initiative supporting the most promising French biotech innovations. This highlights EQT Life Sciences’ expertise in identifying leading European biotech companies and turning them into global success stories.

The transaction is expected to close by the end of Q1 2026, subject to customary closing conditions, including regulatory approvals under French and U.S. regulations.

Contact
EQT Press Office, press@eqtpartners.com

Downloads

About EQT Life Sciences

EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences aims to back the smartest inventors who have ideas that could truly make a difference for patients

More information: https://eqtgroup.com/private-capital/eqt-life-sciences

About ImCheck Therapeutics

ImCheck Therapeutics is developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. By unlocking the power of γ9δ2 T cells, ImCheck’s innovative approach has the potential to transform treatments across oncology, autoimmune, and infectious diseases.

The lead clinical-stage program, ICT01, has been advancing to late-stage trials, demonstrating a unique mechanism of action that modulates both innate and adaptive immunity. These “first-in-class” activating antibodies may deliver superior clinical outcomes compared to first-generation immunotherapy approaches, in particular in rationale combinations with immune checkpoint inhibitors and immunomodulatory anti-cancer drugs. Additionally, ImCheck’s pipeline compounds are progressing toward clinical development for autoimmune and infectious diseases.

The company benefits from the pioneering research of Prof. Daniel Olive (Institut Paoli Calmettes, INSERM, CNRS, Aix-Marseille University), a global leader in γ9δ2 T cells and butyrophilins, as well as the expertise of a seasoned management team and the commitment of leading French, European and U.S. investors including Kurma Partners, Eurazeo, Bpifrance through its Innobio 2 and Large Venture funds, Andera Partners, Pfizer Ventures, Gimv, EQT Life Sciences, Earlybird, Wellington Partners, Pureos Bioventures, Invus, Agent Capital, Boehringer Ingelheim Venture Fund, Alexandria Venture Investments and Blood Cancer United (previously LLS)®

For further information: https://www.imchecktherapeutics.com

Categories: News

Tags:

Gimv Life Sciences realizes successful exit with the sale of its stake in Imcheck Therapeutics to Ipsen

GIMV

Gimv announces the sale of its stake in ImCheck Therapeutics to Ipsen, marking a significant milestone for both companies. This transaction highlights Gimv’s strategic approach to valorizing investments in the life sciences sector, demonstrating how our support for scientific innovation not only creates tangible value for shareholders, but also benefits society at large by advancing the medical field through the introduction of new treatments.

ImCheck Therapeutics, a French biotechnology company, has developed a next-generation antibody pipeline with its lead program, ICT01, showing highly encouraging results in acute myeloid leukemia (AML). The Phase I/II EVICTION trial has demonstrated nearly double the treatment response compared to historical standards, positioning ICT01 as a potential new standard of care for high-risk, unfit AML patients.

Ipsen’s acquisition of all issued and outstanding shares of ImCheck Therapeutics, for a closing purchase price of 350 million euro and potential milestone payments totaling nearly 1 billion euro, reflects the significant value created by ImCheck’s team, scientific founders, and investors. This transaction validates the impact of collaborative investment in transformative healthcare solutions.

Rishabh Chawla, Principal in Gimv’s Life Sciences team declares: “Gimv is proud to have supported ImCheck’s journey from academic research to late-stage clinical development. The sale to Ipsen not only delivers substantial returns to our stakeholders but also ensures that ImCheck’s innovative therapies will reach patients worldwide, backed by Ipsen’s global development and commercialization expertise.

Bram Vanparys, Managing Partner and board member at Imcheck Therapeutics, adds: “This exit highlights Gimv’s strategy of investing in high-potential life sciences companies and partnering with visionary teams to advance medical breakthroughs. We congratulate ImCheck Therapeutics and Ipsen on this landmark transaction and look forward to seeing ICT01 and future pipeline assets make a lasting impact in oncology and beyond.

As a result of this transaction, Gimv will receive an upfront cash payment that represents a realized money multiple of 2.6x on our total investment and a positive impact of approximately 0.4 euro per share compared to the unaudited NAV communicated in the trading update at the beginning of September. Should all regulatory and sales-based milestones be achieved, this could result in a potential total money multiple of 7.1x, subject to the successful completion of these milestones.

The transaction is expected to close by the end of Q1 2026, subject to fulfilment of customary closing conditions including the expiration or termination of any required regulatory and governmental approvals under French and U.S. regulations.

For more information, please read the full press release from Ipsen attached.

Categories: News

Tags:

Southern Home Services Expands Texas Footprint with Acquisition of Nick’s Plumbing & Air Conditioning in Houston

Gryphon Investors

Southern Home Services, a leading residential trade service consolidator, is pleased to announce the acquisition of Nick’s Plumbing & Air Conditioning, a trusted provider of plumbing, heating and air conditioning services in the greater Houston market. This strategic acquisition marks Southern’s fourth location in Texas, strengthening its presence in one of the largest and fastest-growing home services markets in the United States.

“Nick’s Plumbing & Air Conditioning is a fantastic brand and we are excited to welcome them to the Southern family,” said Jarrod Brinker, Chief Strategy Officer for Southern Home Services. “With a large population, high humidity and high summer temperatures, Houston is one of the largest, most dynamic markets in America. This partnership positions us to continue our mission of delivering exceptional plumbing and air conditioning services to even more homeowners across the lower Southeast, Midwest and Mid-Atlantic markets.”

Owner Richard Saad shared his excitement for the next chapter: “Joining forces with Southern Home Services is an exciting step forward for our team and our customers. Southern’s resources, expertise, and commitment to excellence will allow us to continue delivering the high-quality service that Houston homeowners have trusted for years while creating new opportunities for growth and innovation.”

As Southern Home Services integrates Nick’s Plumbing & Air Conditioning into its growing network of brands, the focus will remain on preserving the company’s strong local reputation and providing a seamless experience for customers and employees alike. Nick’s will continue to operate under its current name, ensuring continuity of service and culture.

About Southern Home Services
Southern Home Services, a trusted provider of comprehensive heating, air conditioning, plumbing, and electrical services across the United States, has been enhancing home comfort and safety since 2016. Our certified professionals deliver quality solutions with exceptional customer service, upholding our core values of trust, integrity, and southern charm. We are dedicated to ensuring your home systems operate smoothly, offering reliability and peace of mind in every season. For more information, visit www.southernhomeservices.com.

Categories: News

CourtReserve Secures a $54M Growth Investment from Mainsail Partners to Accelerate Innovation in Racquet & Paddle Club Software

Mainsail partners

St. Augustine, FL — October 21, 2025 — CourtReserve, a leading club management software platform used by more than 2,000 racquet clubs and paddle sports facilities and five million players, today announced that it has secured a $54 million strategic growth investment from Mainsail Partners, a growth equity firm investing in vertical SaaS businesses. The investment will help fuel accelerated product development, enhance customer service and support, deepen integrations, and expand the company’s market reach to sports facilities across North America.

Since its founding in 2016, CourtReserve has grown into a trusted platform, powering court booking, membership management, event programming, payments, and mobile experiences for racquet and paddle sports clubs and their players. With support from Mainsail Partners, CourtReserve will invest heavily in scaling its platform architecture, enhancing AI-driven features, and cultivating new partnerships with recreation organizations, universities, and multi-club operators.

“Over the years, we built CourtReserve with a singular focus. Help clubs run better and scale smarter,” said CEO & Co-Founder, Tim Owens. “Partnering with Mainsail Partners will help fuel us with the capital and operational resources we need to raise the bar even further, so our clubs can spend less time on admin and more time on growth and community.”

“CourtReserve is a clear category leader in racquet sports management because we have a deep understanding of our customers and a product that drives real operational impact,” said Ashley Owens, Co-Founder. “We’re excited for Mainsail Partners’ support as we scale the platform and continue delivering value to clubs and players alike.”

“Ashley and Tim have first-hand experience operating racquet sports clubs, giving them a deep understanding of the complex workflows that can be optimized through software and AI,” said Jason Frankel, Partner at Mainsail Partners. “Combined with a mission-driven culture and the rapid growth of pickleball and racquet sports, we’re excited to support the CourtReserve team as they take their platform to the next level to best serve club owners, players and the racquet sports community.”

Key Investment Focus Areas

  • Platform architecture & performance upgrades — Ensuring scalability and reliability as club adoption grows
  • AI and data features — Enhancing smart automation, member insights, and predictive analytics
  • Integration expansion — Strengthening connections with ratings platforms, access control, accounting, CRM, and marketing tools
  • Go-to-market scaling — Hiring to accelerate sales, customer success, and marketing across new verticals

The deal marks a milestone in CourtReserve’s growth journey and underscores growing demand for modern, cloud-based technology in the racquet and paddle sports technology market. The investment positions CourtReserve to remain a category leader and continue enhancing its value to clubs, facilities and players nationwide.

About CourtReserve

CourtReserve is a racquet & paddle sports club management platform that simplifies operations from court scheduling to memberships, payments, and mobile experiences. Trusted by over 2,000 clubs and 5 million players, CourtReserve helps facilities scale, improve member experience, and focus on community rather than back-office complexity.

About Mainsail Partners

Mainsail Partners is a growth equity firm that invests in bootstrapped B2B software companies to help them grow into market leaders. Our team is purpose-built to include experienced investors and software operators who help founders build great teams, develop industry-leading products, design data-driven and scalable infrastructure, harness the power of AI to drive productivity and innovation, and grow market share. Mainsail’s hands-on support and best practices are delivered through a collaborative approach that respects founder-led cultures and helps build on each company’s commitment to its people and customers. With offices in Austin and San Francisco, Mainsail Partners has raised nearly $4 billion in committed capital and partnered with 100+ companies over the last 22+ years. For more information, visit www.mainsailpartners.com.

Categories: News

Thoma Bravo Announces Key Appointments to Grow Private Credit Platform

Thomas Bravo

Former Morgan Stanley Executives Jeff Levin and Kunal Soni Join as Partners

Levin Named Head of Thoma Bravo Credit

MIAMI and NEW YORK—Thoma Bravo, a leading software investment firm, today announced that Jeff Levin and Kunal Soni have joined the firm as partners on the Thoma Bravo Credit platform. Levin has also been named head of the platform.

Together with the firm’s investors, Thoma Bravo Credit has invested over $25 billion across more than 100 transactions since its inception in 2017. Earlier this year, it successfully closed Thoma Bravo Credit Fund III. Levin and Soni bring decades of experience leading and scaling private credit platforms. They will help drive the next phase of Thoma Bravo Credit’s growth and their addition significantly expands the firm’s origination, structuring, and underwriting capabilities. With deeper credit expertise and greater execution capacity, Thoma Bravo Credit can offer investors broader access to attractive private-credit opportunities while providing borrowers with the flexible, long-term capital they seek to accelerate growth.

Levin was a founding member of Morgan Stanley Investment Management’s Private Credit business and was most recently Co-Head of its North America Private Credit platform. In his role, he served as Portfolio Manager, Head of U.S. Direct Lending, and Chair of the Investment Committee for the U.S. Direct Lending funds. He previously served as a Partner and Managing Director at The Carlyle Group (NASDAQ:CG), where he served as President of Carlyle’s BDCs and as a member of the Investment Committee for their Direct Lending platform.

Soni was most recently the Head of the Western Region and Technology Lending for Morgan Stanley Investment Management’s Private Credit business, where he served as a member of the Investment Committee and focused on originating and executing investment opportunities. Prior to joining Morgan Stanley, Soni was Head of the Western Region for Carlyle’s Direct Lending platform.

“Private credit continues to play an increasingly important role in supporting growing businesses and meeting investor demand for income and diversification,” said Orlando Bravo, a Founder and Managing Partner at Thoma Bravo. “Jeff and Kunal’s leadership strengthens our ability to deliver broader services and compelling investment opportunities to our investors, while expanding our capacity to provide companies with the flexible capital they need to grow and thrive. These appointments reflect our commitment to building a leading, scaled private credit platform positioned to capture attractive opportunities across market cycles.”

“Thoma Bravo Credit has a solid foundation built on discipline, investor alignment, and consistently strong performance,” said Jeff Levin. “Our goal now is to expand the breadth and depth of what we offer so investors can access a broader range of high-quality credit opportunities aligned with their investment objectives, while borrowers can benefit from enhanced expertise and long-term, growth-enabling capital.”

“I’m excited to join Thoma Bravo Credit at such a dynamic time for private credit,” said Kunal Soni. “The market continues to expand and evolve, creating opportunities for platforms with the scale and discipline to meet growing demand. With Thoma Bravo’s reach and resources, we are positioned to deliver meaningful value to both investors and borrowers.”

About Thoma Bravo

Thoma Bravo is one of the largest software-focused investors in the world, with approximately $181 billion in assets under management as of June 30, 2025. Through its private equity, growth equity and credit strategies, the firm invests in growth-oriented, innovative companies operating in the software and technology sectors. Leveraging Thoma Bravo’s deep sector knowledge and strategic and operational expertise, the firm collaborates with its portfolio companies to implement operating best practices and drive growth initiatives. Over the past 20+ years, the firm has acquired or invested in approximately 555 companies representing approximately $285 billion in enterprise value (including control and non-control investments). The firm has offices in Chicago, Dallas, London, Miami, New York, and San Francisco. For more information, visit Thoma Bravo’s website at www.thomabravo.com.

Read the release on the PR Newswire website here.

Categories: News

Tags:

Caylent Acquires Trek10 to Create the Most Comprehensive Dedicated AWS Services Partner in the Industry

Gryphon Investors

Acquisition expands Caylent’s AWS expertise, extending capabilities into managed services to deliver end-to-end customer evolution

Caylent, an Amazon Web Services (AWS) Premier Tier Services Partner, announced it has acquired Trek10 Inc., also an AWS Premier Tier Services Partner, in a strategic move that expands Caylent’s portfolio into managed services and strengthens its ability to deliver end-to-end AWS services for customers. The acquisition is backed by Gryphon Investors, Caylent’s private equity firm, reinforcing the company’s growth strategy and commitment to AWS excellence. Lazard served as exclusive financial advisor to Trek10 in connection with the transaction.

“This combination establishes the most comprehensive dedicated AWS services partner in the industry,” said Lori Williams, CEO of Caylent. “By uniting Trek10’s proven CloudOps platform and managed services capabilities with Caylent’s agentic delivery model, we are delivering full-lifecycle AI-era services focused on enhancing customer outcomes. Organizations now have a single partner to guide their evolution on AWS with AI-powered speed, software-like scalability, and continuous optimization built in.”

Shared AWS Leadership and Capabilities

For the industry, this strategic combination brings together two AWS leaders to form a cloud expertise powerhouse, uniting deep strategy and engineering capabilities across migration and modernization, data and analytics, generative AI, and DevOps. The combined company delivers unparalleled AWS expertise, leveraging Caylent’s proven track record as a six-time AWS Partner of the Year award winner and Trek10’s specialized AWS IoT, Travel and Hospitality and Retail Competency credentials. This strategic alliance positions the combined entity to deliver exceptional value to clients while exploring expanded market opportunities, including potential growth into EMEA regions.

End-to-End Cloud Journey Capabilities

The combined company delivers consulting, engineering, and managed services to support customers across their entire AWS journey through:

  • Forward Deployed Strategy: Shorten time to value by partnering with customers at the intersection of business and technology to shape cloud-first strategies, operating models, and organizational change initiatives, tying execution to measurable business outcomes.
  • Agentified Migration and Modernization Services: Cut migration, data modernization and application rewrite timelines by applying AI automation, proven frameworks, and Caylent Accelerate™ IP, enabling customers to lower risk and downtime while delivering resilient, high-performing AWS environments.
  • Custom Product Innovation Services: Accelerate the delivery of new digital experiences and help customers remain competitive by building machine-learning platforms, serverless applications, and AI solutions through integrated product strategy, cloud architecture, and engineering expertise.
  • Managed Services: Maintain enterprise-scale security, availability, and reliability by managing customers’ AWS environments through Trek10’s CloudOps platform with 24/7 monitoring, 15-minute response times, and continuous optimization delivered by AWS experts.

“Joining forces with Caylent unlocks extraordinary opportunities for our customers,” said Shane Fimbel, CEO of Trek10. “Our teams share a commitment to AWS excellence and innovation. By combining Caylent’s agentified services with Trek10’s CloudOps expertise, we’re giving customers a single partner to enable and accelerate every stage of their AWS journey, from strategy and migration to operations and next-generation AI.”

About Caylent
As an AWS Premier Tier Services Partner, Caylent is shaping the future where AI transforms industries responsibly and with excellence. We help companies build the solutions they need to succeed in today’s market while enabling organizational evolution to thrive in a rapidly changing technology landscape. Our AI-enabled delivery methodology combined with our deep AWS experience turns our customers’ ideas into impact, faster.

Caylent’s achievements include being named AWS Migration Consulting Partner of the Year, GenAI Industry Solution Partner of the Year, and Industry Partner of the Year – Financial Services in 2024, Application Modernization Partner of the Year in 2023, AWS Innovation Partner of the Year in 2022, and AWS Rising Star Partner of the Year in 2021. Caylent’s services include migrations, modernization, custom software development and generative AI. Learn more at https://caylent.com/

About Trek10
Founded in 2013, Trek10 focuses on helping organizations migrate to and maximize the benefits of AWS services. They put their effort into designing, building, and supporting AWS workloads with the right team of certified AWS experts to help—regardless of the customer’s situation. From thought-leading content to a deep collaboration with AWS to build and sustain modern cloud ecosystems, clients trust Trek10’s expertise, passion, and commitment to cloud modernization efforts.

About Gryphon Investors
Gryphon Investors is a leading middle-market private investment firm focused on profitably growing and competitively advantaged companies in the Business Services, Consumer, Healthcare, Industrial Growth, Software, and Technology Solutions & Services sectors. With more than $10 billion of assets under management, Gryphon prioritizes investments in which it can form strong partnerships with founders, owners, and executives to accelerate the building of leading companies and generate enduring value through its integrated deal and operations business model. Gryphon’s highly differentiated model integrates its well-proven Operations Resources Group, which is led by full-time, Gryphon senior operating executives with general management, human capital acquisition and development, treasury, finance, and accounting expertise. Gryphon’s three core investment strategies include its Flagship, Heritage, and Junior Capital strategies, each with dedicated funds of capital. The Flagship and Heritage strategies target equity investments of $50 million to $500 million per portfolio company. The Junior Capital strategy targets investments of $10 million to $25 million in junior securities of credit facilities, arranged by leading middle-market lenders, in both Gryphon-controlled companies, as well as in other private equity-backed companies operating in Gryphon’s targeted investment sectors.

Categories: News

Tags:

La Caisse entrusts management of its Québec office properties to Canderel

LaCaisse

La Caisse announces the conclusion of a strategic partnership with Canderel—a major private real estate company headquartered in Montréal—to take over the operational management of its Québec office properties while retaining ownership.

“In addition to supporting a fast-growing Québec real estate leader, this partnership will enable La Caisse to focus fully on its core profession as an investor and standardize its real estate business model,” said Annie Houle, Managing Director, Real Estate, Canada, at La Caisse.

Built on shared interests, this partnership aims to preserve the distinctive character of symbolic Quebec buildings owned by La Caisse, such as Place Ville Marie, Édifice Jacques-Parizeau and Édifice Price, and to ensure the continuity and quality of the services offered.

“It’s a great privilege for Canderel to be entrusted with the management of such iconic buildings. This mandate demonstrates La Caisse’s confidence in our expertise and our roots in Québec, and we are proud to contribute to the stewardship of this exceptional real estate heritage,” said Brett Miller, Chief Executive Officer at Canderel.

On December 1, 2025, all teams currently involved in La Caisse’s office building operations in Québec will join Canderel, ensuring a smooth transition that respects existing expertise.

ABOUT LA CAISSE

At La Caisse, formerly CDPQ, we have invested for 60 years with a dual mandate: generate optimal long term returns for our 48 depositors, who represent over 6 million Quebecers, and contribute to Québec’s economic development.

As a global investment group, we are active in the major financial markets, private equity, infrastructure, real estate and private credit. As at June 30, 2025, La Caisse’s net assets totalled CAD 496 billion. For more information, visit lacaisse.com or consult our LinkedIn or Instagram pages.

La Caisse is a registered trademark of Caisse de dépôt et placement du Québec that is protected in Canada and other jurisdictions and licensed for use by its subsidiaries.

ABOUT CANDEREL

Canderel is one of the largest private real estate companies in Canada. With its head office located in Montréal and six other offices nationwide, Canderel has been part of the Canadian real estate landscape for 50 years. Benefiting from the expertise of nearly 650 real estate professionals, Canderel has developed unique know-how and positioning in value creation, performance optimisation, and improving returns on real estate investments. Since its inception, the company has managed more than $20 billion in acquisitions, development, and management projects, totalling over 80 million square feet of owned, managed and developed properties.

– 30 –

For more information

Categories: News

Tags:

Peter Herweck Joins Warburg Pincus as Executive-in-Residence to Support European Technology Group

Warburg Pincus logo

Former CEO of Schneider Electric Brings Global Industrial and Software Leadership Experience

London, 21 October 2025 – Warburg Pincus, the pioneer of private equity global growth investing, today announced the appointment of Peter Herweck as an Executive-in-Residence, working with the firm’s European Technology group. In his role, Mr. Herweck will work with Warburg Pincus to identify and evaluate new investment opportunities across the software and technology sectors. He will also play an active role in value creation across the firm’s existing portfolio.

Mr. Herweck brings over three decades of global operating experience and deep sector expertise across industrial automation, industrial software, and energy systems. Most recently, he served as CEO of Schneider Electric, having previously been Chairman and CEO of AVEVA. Prior to that, he held multiple senior executive roles at Siemens, including Chief Strategy Officer of the Group.

“I am delighted to be joining Warburg Pincus to support the firm’s continued investment efforts in transformative technology businesses”, said Peter Herweck. “Throughout my career, I have been focused on how innovation drives efficiency, safety, and sustainability.”

“We are truly excited to partner with Peter,” said Carl von Baumbach, Principal at Warburg Pincus. “His strategic insight, deep domain knowledge and experience in scaling global technology platforms will be immensely valuable as we continue to invest behind secular technology trends and support our portfolio companies in unlocking their full potential.”

Mr. Herweck currently serves as Non-Executive Director on Teradyne’s (TER) board. He holds an MBA from Wake Forest University, completed the Advanced Management Program at Harvard Business School, and holds engineering degrees from Université de Metz (France) and HTW Saar (Germany).

Media contact:

Alice Gibb
Director, Europe Communications
Alice.gibb@warburgpincus.com
+44 207 306 3090

About Warburg Pincus

Warburg Pincus LLC is the pioneer of global growth investing. A private partnership since 1966, the firm has the flexibility and experience to focus on helping investors and management teams achieve enduring success across market cycles. Today, the firm has more than $86 billion in assets under management, and more than 220 companies in their active portfolio, diversified across stages, sectors, and geographies. Warburg Pincus has invested in more than 1,000 companies across its private equity, real estate, and capital solutions strategies.

The firm is headquartered in New York with offices in Amsterdam, Beijing, Berlin, Hong Kong, Houston, London, Luxembourg, Mumbai, Mauritius, San Francisco, São Paulo, Shanghai, and Singapore. For more information, please visit www.warburgpincus.com or follow us on LinkedIn.

Back To News

Categories: People

Fortitude Re and Carlyle Establish FCA Re with Over $700 Million of Capital to Drive Continued Growth in Asia

No Comments
Carlyle

HAMILTON, BERMUDA – October 21, 2025 – FGH Parent, L.P., (“FGP” and together with its subsidiaries, “Fortitude Re”), a leading global reinsurance company, and global investment firm Carlyle (NASDAQ: CG) today announced the launch of reinsurance sidecar Fortitude Carlyle Asia Reinsurance, Ltd. (“FCA Re”).

FCA Re is a Class E licensed Bermuda-domiciled reinsurer established to accelerate Fortitude Re’s growth in the Asian life and annuity market. FCA Re will initially assume a share of existing liabilities from Fortitude Re and will also reinsure a share of Fortitude Re’s future transactions in Asia.

FCA Re has more than $700 million in deployable capital, including equity and expected debt capacity. FCA Re has secured equity commitments from Fortitude Re, Carlyle, and a group of global institutional investors including T&D Insurance Group, AllianceBernstein, Shinhan Life, and National Pension Service of Korea (“NPS”), among others.

Fortitude Re will serve as insurance sponsor and Carlyle will serve as asset management sponsor to FCA Re. Once its capital is fully deployed, FCA Re is expected to add approximately $10 billion of fee-earning assets under management to Carlyle.

“Fortitude Re has already reinsured approximately $15 billion in reserves on behalf of clients in Asia and we are dedicated to making further investments in the region,” said Alon Neches, Chief Executive Officer of Fortitude Re. “FCA Re will help us continue delivering solutions that drive our clients’ strategies forward.”

Asia represents one of the most dynamic and attractive opportunities in global reinsurance today, driven by aging demographics and a growing need for insurers to rethink how they manage capital, risk, and long-duration liabilities.

“FCA Re is a natural extension of Carlyle’s strategy to deliver integrated asset, capital and liability solutions to insurance clients worldwide,” said Brian Schreiber, Partner at Carlyle and Head of Carlyle Insurance Solutions. “Through FCA Re, we are further demonstrating that the most sophisticated insurance investors globally are choosing to access the Asian market by partnering with one of the world’s most accomplished reinsurers and one of the largest global investment firms. With Carlyle’s more than 25-year history and deep experience in Asia, we are excited to continue to drive growth in the region.”

J.P. Morgan Securities, LLC acted as financial advisor and Debevoise & Plimpton LLP acted as legal advisor to the sponsors and FCA Re.

About Fortitude Re

Fortitude Re is a leading provider of reinsurance solutions with $105 billion in total assets as of Dec. 31, 2024. The foundations of our business model are our exceptional insurance professionals and the support of the world’s most sophisticated insurance investors, including Carlyle and T&D Insurance Group. Our people, our capital strength and our capabilities drive strategic reinsurance solutions designed to meet our clients’ highest priority goals and to create sustainable, long-term value for our shareholders, our teammates, and the communities in which we operate. For more information visit, www.fortitude-re.com and follow Fortitude Re on LinkedIn.

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $465 billion of assets under management as of June 30, 2025, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,300 people in 27 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

 

Media Contacts

 

Fortitude Re

Mary Beth Conklin
Marybeth.conklin@fortitude-re.com

SVP, Marketing and Communications

 

Carlyle

Kristen Ashton

Kristen.ashton@carlyle.com

Corporate and Financial Communications

 

Lonna Leong

Lonna.leong@carlyle.com

Head of Asia Pacific Corporate Communications

 

Andrew Kenny

Andrew.kenny@carlyle.com

Head of EMEA and Japan Corporate Communications

Categories: News

Tags: